Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RARB | P10826 | 12/20 | 0.63 |
| ▸ | RARG | P13631 | 12/20 | 0.63 |
| ▸ | CYP26A1 | O43174 | 3/20 | 0.63 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.63 |
| ▸ | RXRA | P19793 | 9/20 | 0.56 |
| ▸ | RARA | P10276 | 11/20 | 0.55 |
| ▸ | RXRB | P28702 | 5/20 | 0.53 |
| ▸ | CYP26B1 | Q9NR63 | 2/20 | 0.49 |
| ▸ | RXRG | P48443 | 3/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30477013 | 0.77 | RARB (1.00) | RARBRARGCYP26A1CYP3A4RXRA | |
| SCHEMBL3756112 | 0.77 | RARB (1.00) | RARBRARGCYP26A1CYP3A4RXRA | |
| SCHEMBL29613246 | 0.77 | RARB (1.00) | RARBRARGCYP26A1CYP3A4RXRA | |
| SCHEMBL29354207 | 0.77 | RARB (1.00) | RARBRARGCYP26A1CYP3A4RXRA | |
| SCHEMBL165750 | 0.77 | RARB (1.00) | RARBRARGCYP26A1CYP3A4RXRA | |
| SCHEMBL165751 | 0.77 | RARB (1.00) | RARBRARGCYP26A1CYP3A4RXRA | |
| SCHEMBL8458824 | 0.72 | RXRA (1.00) | RARBRARGCYP26A1CYP3A4RXRA | |
| SCHEMBL20646221 | 0.72 | RXRA (0.70) | RARBRARGCYP26A1CYP3A4RXRA | |
| SCHEMBL7871498 | 0.72 | RXRA (0.64) | RARBRARGCYP26A1CYP3A4RXRA | |
| SCHEMBL9350200 | 0.72 | RXRA (0.64) | RARBRARGCYP26A1CYP3A4RXRA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11466252-B2 | Expansion and differentiation of inner ear supporting cells and methods of use thereof | MASSACHUSETTS EYE AND EAR INFIRMARY (US) | 2022-10-11 | — | — | US | disclosed |
| US-20220192984-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING OTIC THERAPEUTIC AGENTS AND RELATED METHODS | Frequency Therapeutics, Inc. | 2022-06-23 | — | — | US | disclosed |
| US-20190010449-A1 | Expansion and Differentiation of Inner Ear Supporting Cells and Methods of Use Thereof | MASSACHUSETTS EYE AND EAR INFIRMARY | 2019-01-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220192984-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING OTIC THERAPEUTIC AGENTS AND RELATED METHODS | OTC, EXOSC5, ENTPD5 | RARB 3812/4885RARG 2844/4885CYP26A1 3095/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.